Every regulatory submission team has lived through the same scenario. The SDTM datasets are mapped, the ADaM derivations are programmed, the SEND package is back from the vendor, and the validator shows a clean report. Then the FDA reviewer opens the data and the problems start.
PointCross Life Sciences has processed thousands of nonclinical and clinical studies across IND, NDA, and BLA submissions. The patterns that cause validation failures and submission delays are remarkably consistent, and remarkably preventable, if you know where to look and when to check.
This article breaks down the specific failure modes across SDTM, ADaM, and SEND datasets, identifies the review checkpoints that catch them, and outlines how clinical data management and biostatistics teams can prevent the rework that derails submission timelines.
What Are the Most Common SDTM Validation Failures?
SDTM validation failures cluster around three categories: controlled terminology mismatches, timing variable errors, and structural non-conformance.
Controlled terminology issues are the single most frequent finding. They happen when variable values do not match CDISC Controlled Terminology, when capitalization is inconsistent across domains, or when teams use an outdated CT version that no longer aligns with the submission window. The root cause is usually upstream: clinical sites entering free-text values instead of standardized options in the EDC, or CRF codelist designs that were never reconciled against the CDISC CT package applicable to the study.
Timing variable errors rank second. ISO 8601 date format inconsistencies, missing reference start dates (RFSTDTC in DM), incorrect study day derivations, and visit names that do not match the trial design datasets all trigger conformance findings. These are not trivial formatting issues. Timing data drives treatment-emergent adverse event classification, endpoint windowing, and safety assessments. When timing variables are wrong, downstream ADaM derivations inherit the problem.
Structural failures include missing required variables, improperly populated supplemental qualifiers (SUPP domains), and domain-level conformance issues such as record uniqueness violations. The FDAβs Technical Rejection Criteria require specific datasets to be present and correctly named: ts.xpt, dm.xpt, and a valid define.xml are non-negotiable. A submission missing any of these faces automatic rejection before a reviewer examines the science.
The STUDYID variable in the Trial Summary dataset must match the value in the Study Tagging File (stf.xml). If they do not match, the TS dataset is not considered valid, regardless of how complete the rest of the package looks.
Why Does Passing the Validator Not Mean Your Data Is Submission-Ready?
This is the question that catches the most experienced teams off guard. Conformance validation tools check that your datasets follow the structural rules of the applicable implementation guide: correct variable names, correct data types, required fields populated, valid controlled terminology applied. They run hundreds of checks, and they are essential.
But conformance and data quality are different things.
A conformant dataset can still be scientifically inaccurate. SEND datasets illustrate this clearly. The FDAβs March 2026 Study Data Technical Conformance Guide (TCG) dedicates an entire appendix to SEND verification practices because the agency observed a recurring problem: SEND packages that pass conformance validation but cannot reproduce the results published in the audited GLP Study Report.
Group means that do not reconcile, incidence counts that cannot be reproduced, and set definitions that do not reflect what the study report describes are all invisible to conformance validators because the validators were never designed to catch them.
The TCG organizes SEND usability failures into three categories. Submission-level issues cover structural assembly problems within the eCTD, such as files placed in incorrect folder locations or datasets from multiple studies in the same folder. SENDIG conformance violations cover what validators detect, including record uniqueness violations, empty required variables, and invalid cross-file references. Data representation failures cover discrepancies between the SEND dataset and the study report, which is the category that delays programs and which no automated tool can detect without structured reconciliation against the final report.
For clinical SDTM and ADaM datasets, the equivalent risk manifests as metadata mismatches: Define-XML saying a variable is numeric while the dataset stores it as character, derivation descriptions that say βDerived per SAPβ without summarizing the rule, or value-level metadata that omits cases where a variableβs meaning changes depending on the parameter.
What ADaM-Specific Issues Cause the Most Rework?
ADaM validation failures center on traceability gaps, derivation inconsistencies, and population flag misalignment.
Traceability is the defining requirement of ADaM. Every analysis variable must trace back to its SDTM source, documented through Define-XML metadata. When a reviewer sees a derived tumor response or a change-from-baseline efficacy value and cannot follow the chain from ADaM back to SDTM, the entire analytical conclusion comes into question. Resolving this requires carrying source values or reference keys through the dataset so that any downstream number can be independently verified against the original SDTM records.
Derivation inconsistencies are the second major source. The most common: CHG (change from baseline) values that do not equal AVAL minus BASE due to numerical precision differences between the programming environment and the validation tool. AVALC values that include leading zeros or special characters inconsistent with the corresponding AVAL. Datetime variables ending in DTM that lack the required SAS datetime format. These are mechanical, but they consume disproportionate QC time when discovered late.
Population flag misalignment between ADSL and analysis datasets creates a third failure category. If ADSL defines SAFFL = Y for 247 subjects but a downstream ADAE analysis filters to 245 without explanation, the reviewer must resolve the discrepancy before interpreting results. This misalignment often originates from parallel development tracks where ADSL and BDS datasets are programmed concurrently without a reconciliation checkpoint.
The sequencing between SDTM and ADaM programming also matters. ADaM derivations depend on validated SDTM source variables. When teams start ADaM programming before SDTM domains are finalized, any SDTM change forces rework of every downstream ADaM dataset that references the modified variables. This can add weeks to submission timelines.
How Do Define-XML Gaps Create Downstream Validation Failures?
Define-XML is the contract between your datasets and the reviewer. It describes every dataset, every variable, and every derivation in a machine-readable format that the reviewerβs tools parse directly. When the contract does not match the product, the result is confusion, conformance errors, and review delays.
The most consequential Define-XML failures are variables present in datasets but missing from the define (or vice versa), incorrect data types, incomplete derivation descriptions for ADaM variables, and missing value-level metadata for variables whose meaning varies by parameter.
Many teams treat Define-XML as a documentation step that happens at the end of dataset development. That approach guarantees misalignment. Every time a mapping specification changes, a variable is added or dropped, or a derivation algorithm is updated, the define drifts further from reality. By the time someone generates the final Define-XML, the reconciliation effort is substantial, and the risk of shipping undetected mismatches is high.
The more effective approach is maintaining metadata throughout development. When the define is built and updated alongside the datasets, discrepancies surface immediately, and the effort to produce a submission-ready define is incremental rather than a final-stage project.
The eDataValidator (eDV) from PointCross Life Sciences validates Define-XML against CDISC, FDA, and PMDA rules, catching misalignment between datasets and metadata before the submission package is assembled.
Where Do SEND Datasets Fail Beyond the Conformance Check?
SEND presents a validation challenge that is structurally different from SDTM or ADaM. In most organizations, the Study Report and the SEND dataset are produced by two separate teams running two separate processes from the same underlying study data but without a shared data model connecting them.
This creates a predictable divergence. The Study Report team finalizes the report. Then the SEND team begins, extracting, re-integrating, and rebuilding data that was already built once. Every step of that duplication introduces opportunities for inconsistency.
The FDAβs TCG identifies the specific failure modes. Group summary means in the SEND dataset that do not match the summary tables in the study report. Incorrect set definitions, such as terminal and recovery animals placed in the same set. Qualitative incidence counts that cannot be reproduced from the SEND data. Multiple records for the same animal, endpoint, day, and timepoint with conflicting values.
These failures do not generate validator error codes. They remain invisible until an FDA reviewer attempts to use the data, at which point the submission is classified as unusable, not merely incomplete.
PointCross Life Sciences addresses this through two paths. For studies where PointCross generates SEND from the start, the Universal Data Model (UDM) feeds both the Study Report and the SEND dataset concurrently, eliminating the structural conditions for divergence. For studies where a CRO or third-party vendor has already delivered a SEND package, the SEND ASSURE service provides an independent reconciliation audit, comparing the submitted SEND dataset domain by domain against independently regenerated reference files built solely from the final study report.
What Review Checkpoints Catch Validation Issues Before They Reach the FDA?
The distinction between teams that submit clean datasets and teams that rework packages under deadline pressure usually comes down to when they validate, not whether.
CRF design review is the first checkpoint. Aligning EDC codelists against the applicable CDISC CT package before the first patient is enrolled prevents the most common source of controlled terminology findings. If the CRF captures free text where a standardized term is required, no amount of downstream mapping will fully compensate.
Early and iterative validation is the second. Running conformance validation after SDTM draft completion, before ADaM development begins, and again after ADaM is complete catches issues when they are less expensive to fix. Waiting for the final dataset freeze guarantees that every correction competes with the submission timeline.
SDTM-to-ADaM sequencing controls are the third. Freezing SDTM domains before ADaM programming begins, and re-validating SDTM when any source data changes, prevents the cascading rework that occurs when ADaM derivations reference variables that subsequently change.
Structured reconciliation is the fourth, and it applies specifically to SEND. Checking conformance is necessary. Verifying that every group mean, every incidence count, and every set definition in the SEND dataset can be independently reproduced from the study report is what separates a technically valid package from one that is reviewer-ready.
The fifth checkpoint is Define-XML verification. Comparing the define against the final datasets using automated tools, not manual review, catches the metadata mismatches that create reviewer confusion and trigger conformance findings.
How Do You Build a Validation Strategy That Prevents Rework?
Prevention starts with treating validation as a process that runs from study start to submission, not as a final gate.
Align your data collection instruments with CDISC standards during protocol development. Specify external data transfer formats and controlled terminology versions before the first data point is collected. When your CRF design, EDC codelists, mapping specifications, and target CDISC IG version are all aligned at study start, the most common validation failures never materialize.
Automate what can be automated. Automated SDTM generation from EDC data, metadata-driven programming that propagates specification changes to both datasets and Define-XML simultaneously, and continuous validation integrated into the programming workflow all reduce the surface area for human error.
Investigate root causes, not findings. A validation finding is a symptom. When a controlled terminology error appears in 17 records across three domains, the root cause is likely a mapping specification that references the wrong CT version, not 17 independent data entry mistakes. Fixing the root cause once prevents recurrence. Fixing individual records creates a maintenance burden that compounds with every data refresh.
Document what you accept. Some validation findings reflect justified study-specific implementations that cannot be resolved without changing the underlying data. The Study Data Reviewerβs Guide (SDRG) and the Analysis Data Reviewerβs Guide (ADRG) are the correct vehicles for explaining these decisions to reviewers. A finding that is anticipated, documented, and rationalized is categorically different from one that surprises both the team and the reviewer.
PointCross Life Sciencesβ Xbiom platform supports this approach from study start through submission. The XBIOM Metadata Repository (MDR) provides a structured foundation for managing regulatory and study metadata, ensuring that standardization decisions made at study start propagate through to the final submission package. Combined with the eDataValidator for conformance checking and SEND ASSURE for reconciliation, the platform addresses validation at every stage where failures typically originate.
Clinical data management and biostatistics teams that build these practices into their operating model spend less time on rework and more time on the activities that actually advance their programs: analyzing data, preparing reviewable packages, and meeting submission timelines.